Which patients is Ivonib (Ivitinib) suitable for and how effective is it?

Ivonib (ivitinib) is a targeted anti-cancer drug that targetsIDH1 susceptibility mutations, providing a new treatment option for patients with specific types of cancer. The drug mainly inhibits the activity of mutant isocitrate dehydrogenase 1 (IDH1) enzyme and blocks the formation of the tumor metabolite 2-hydroxyglutarate (2HG) in leukemia cells, thereby reducing the number of IDH1-expressing tumor cells and increasing the percentage of mature myeloid cells. Ivonib has a wide range of clinical applications and is suitable for patients with various types of cancer. It is already on the market in my country and can be purchased in pharmacies with medical advice.

Avosidenib is mainly suitable for the following patient groups: First, for newly diagnosed acute myeloid leukemia (AML) patients, if they are accompanied by susceptible IDH1 mutations, and the patient is 75 years or older, or has comorbidities that prevent the use of intensive induction chemotherapy, Ivosidenib can be used in combination with azacitidine or as a monotherapy, providing patients with an effective treatment option. Secondly, for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have susceptible IDH1 mutations, ivonib can significantly extend the patient's survival and improve their quality of life. In addition, ivosidenib is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndrome (MDS) who also have predisposing IDH1 mutations. Finally, ivonib also shows potential therapeutic value for previously treated adult patients with locally advanced or metastatic cholangiocarcinoma harboring IDH1 mutations. Clinical data show that ivonib has good efficacy and safety, can significantly extend the progression-free survival of patients, and reduce the risk of disease progression. However, this drug is a prescription drug, so be sure to consult your doctor before taking it to make sure it is suitable for your condition.

In addition to the original drug, patients can also choose to purchase affordable generic drugs of ivonib. The generic version of Avonib produced by Lucius Pharmaceuticals in Laos is usually 250mg*60 tablets, and the price is about more than 4,000 yuan per box, providing patients with more treatment options. However, whether it is an original drug or a generic drug, patients should strictly follow the doctor's instructions when using it to ensure the safety and effectiveness of the drug.

To sum up, ivonib (ivitinib), as a targeted anti-cancer drug targeting IDH1 susceptibility mutations, provides a new treatment option for patients with specific types of cancer. Its unique mechanism of action, wide range of applications, and good efficacy and safety make ivonib important and valuable in cancer treatment.

Reference materials:https://www.drugs.com/pro/tibsovo.html#s-42231-1